Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA

Neumora Therapeutics, Inc.

2024-Q1 EPS reported -$0.34

Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.
Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.
Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.
NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.
FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.

Period: the first quarter ended March 31, 2024
Net income: net loss of $53.7 million
Result: reported results

Exact text from the filing

announced its financial results for the first quarter ended March 31, 2024

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.